New Delhi: In a striking reminder of the ongoing challenges in India's pharmaceutical quality ecosystem, 63 batches of widely used medicines have been declared "Not of Standard Quality (NSQ)" by laboratories under the Central Drugs Standard Control Organization (CDSCO) during October 2025.

The flagged products span both life-saving injectables and common daily medications, raising alarm about patient safety and manufacturing compliance in the country.

These include Paracetamol Tablets IP 500 mg manufactured by Bengal Chemicals and Pharmaceuticals, Clopidogrel and Aspirin Tablets IP (75 mg/75 mg) manufactured by Zee Laboratories, Liposomal Amphotericin B Injection 50 Mg (Gufisome) manufactured by Gufic Biosciences, Bupivacaine Hydrochloride in Dextrose Injection USP (Bupivacaine Heavy) m

See Full Page